Free Trial

Cabaletta Bio (CABA) 10K Form and Latest SEC Filings 2026

Cabaletta Bio logo
$4.15 +0.32 (+8.36%)
Closing price 04:00 PM Eastern
Extended Trading
$4.13 -0.02 (-0.48%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Cabaletta Bio SEC Filings & Recent Activity

Cabaletta Bio (NASDAQ:CABA) has submitted 320+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on May 4, 2026.

Form 4
Cabaletta Bio, Inc. Reports Ownership Change on Mar. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Cabaletta Bio Files Current Report on May. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Cabaletta Bio Files Annual Report on Mar. 23, 2026

The 10-K contains Cabaletta Bio's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Cabaletta Bio SEC Filing History

Browse Cabaletta Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 5:37 AM
Cabaletta Bio (1759138) Filer
Form 424B5
05/04/2026 5:40 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/04/2026 5:02 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2026 6:41 AM
Cabaletta Bio (1759138) Filer
Form ARS
04/28/2026 6:31 AM
Cabaletta Bio (1759138) Filer
Form DEF 14A
04/28/2026 6:35 AM
Cabaletta Bio (1759138) Filer
Form DEFA14A
04/20/2026 6:01 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 6:45 AM
Cabaletta Bio (1759138) Filer
Form PRE 14A
03/23/2026 6:36 AM
Cabaletta Bio (1759138) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/23/2026 6:42 AM
Cabaletta Bio (1759138) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/23/2026 6:32 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/02/2026 6:28 PM
Cabaletta Bio (1759138) Issuer
Das Arun (1903997) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:27 PM
Cabaletta Bio (1759138) Issuer
Gerard Michael (1881529) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:18 PM
Cabaletta Bio (1759138) Issuer
Marda Anup (1790410) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:21 PM
Cabaletta Bio (1759138) Issuer
Nichtberger Steven (1487989) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:24 PM
Cabaletta Bio (1759138) Issuer
Chang David J. (1790552) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:26 PM
Binder Gwendolyn (1791742) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 2:00 PM
Cabaletta Bio (1759138) Subject
Cormorant Asset Management, LP (1583977) Filed by
Form SCHEDULE 13G/A
02/17/2026 9:28 AM
Cabaletta Bio (1759138) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
01/21/2026 5:53 PM
Cabaletta Bio (1759138) Issuer
Gerard Michael (1881529) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:53 PM
Cabaletta Bio (1759138) Issuer
Simon Mark (1400717) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:54 PM
Cabaletta Bio (1759138) Issuer
Nichtberger Steven (1487989) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:54 PM
Bollard Catherine (1790411) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:55 PM
Cabaletta Bio (1759138) Issuer
Gavel Steve (2090785) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:55 PM
Cabaletta Bio (1759138) Issuer
Tomasello Shawn (1617239) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:56 PM
Binder Gwendolyn (1791742) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 5:56 PM
Cabaletta Bio (1759138) Issuer
Chang David J. (1790552) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 7:02 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 7:06 PM
Alyeska Investment Group, L.P. (1453072) Filed by
Cabaletta Bio (1759138) Subject
Form SCHEDULE 13G/A
11/14/2025 12:10 PM
Cabaletta Bio (1759138) Subject
Cormorant Asset Management, LP (1583977) Filed by
Form SCHEDULE 13G/A
11/10/2025 6:33 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/10/2025 6:37 AM
Cabaletta Bio (1759138) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/07/2025 12:56 PM
Cabaletta Bio (1759138) Subject
PRUDENTIAL FINANCIAL INC (1137774) Filed by
Form SCHEDULE 13G/A
11/07/2025 12:00 PM
Cabaletta Bio (1759138) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
11/07/2025 12:02 PM
Cabaletta Bio (1759138) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
11/05/2025 12:26 PM
Cabaletta Bio (1759138) Subject
JENNISON ASSOCIATES LLC (53417) Filed by
Form SCHEDULE 13G/A
10/29/2025 6:01 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/27/2025 6:02 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2025 3:31 PM
Cabaletta Bio (1759138) Issuer
Gavel Steve (2090785) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/15/2025 3:39 PM
Cabaletta Bio (1759138) Issuer
Gavel Steve (2090785) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2025 11:03 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/03/2025 5:03 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/17/2025 11:15 PM
Cabaletta Bio (1759138) Filer
Form EFFECT
08/14/2025 4:29 PM
Alyeska Investment Group, L.P. (1453072) Filed by
Cabaletta Bio (1759138) Subject
Form SCHEDULE 13G
08/14/2025 2:02 PM
Cabaletta Bio (1759138) Subject
Cormorant Asset Management, LP (1583977) Filed by
Form SCHEDULE 13G
08/12/2025 8:04 AM
Adage Capital Management, L.P. (1535978) Filed by
Cabaletta Bio (1759138) Subject
Form SCHEDULE 13G/A
08/11/2025 3:27 PM
Cabaletta Bio (1759138) Subject
Nichtberger Steven (1487989) Filed by
Form SCHEDULE 13G/A
08/07/2025 7:26 AM
Cabaletta Bio (1759138) Filer
Form S-3
Registration statement under Securities Act of 1933  
08/07/2025 6:41 AM
Cabaletta Bio (1759138) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2025 6:37 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2025 1:19 PM
Cabaletta Bio (1759138) Subject
PRUDENTIAL FINANCIAL INC (1137774) Filed by
Form SCHEDULE 13G/A
07/29/2025 10:23 AM
Cabaletta Bio (1759138) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
07/16/2025 6:02 PM
BlackRock, Inc. (2012383) Filed by
Cabaletta Bio (1759138) Subject
Form SCHEDULE 13G/A
06/20/2025 4:22 PM
Cabaletta Bio (1759138) Subject
CITADEL ADVISORS LLC (1423053) Filed by
Form SCHEDULE 13G
06/12/2025 5:03 AM
Cabaletta Bio (1759138) Filer
Form 424B5
06/12/2025 5:05 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2025 5:36 AM
Cabaletta Bio (1759138) Filer
Form 424B5
06/11/2025 5:11 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/09/2025 7:22 PM
Brun Scott C. (1863614) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:28 PM
Cabaletta Bio (1759138) Issuer
Simon Mark (1400717) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:16 PM
Cabaletta Bio (1759138) Issuer
HENRIQUES RICHARD C JR (1181178) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:17 PM
Cabaletta Bio (1759138) Issuer
Tomasello Shawn (1617239) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 7:20 PM
Bollard Catherine (1790411) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:38 PM
Cabaletta Bio (1759138) Issuer
Tomasello Shawn (1617239) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:39 PM
Cabaletta Bio (1759138) Issuer
HENRIQUES RICHARD C JR (1181178) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:39 PM
Cabaletta Bio (1759138) Issuer
Gerard Michael (1881529) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:40 PM
Cabaletta Bio (1759138) Issuer
Nichtberger Steven (1487989) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:44 PM
Brun Scott C. (1863614) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:33 PM
Cabaletta Bio (1759138) Issuer
Chang David J. (1790552) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:34 PM
Bollard Catherine (1790411) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:34 PM
Cabaletta Bio (1759138) Issuer
Das Arun (1903997) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:36 PM
Binder Gwendolyn (1791742) Reporting
Cabaletta Bio (1759138) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:36 PM
Cabaletta Bio (1759138) Issuer
Simon Mark (1400717) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 8:36 PM
Cabaletta Bio (1759138) Issuer
Marda Anup (1790410) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 4:22 PM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025 6:05 AM
Cabaletta Bio (1759138) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025 6:10 AM
Cabaletta Bio (1759138) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/13/2025 7:00 AM
Cabaletta Bio (1759138) Filer
Form DEF 14A
05/13/2025 7:02 AM
Cabaletta Bio (1759138) Filer
Form ARS
(Data available from 1/1/2016 forward)

Cabaletta Bio SEC Filings - Frequently Asked Questions

Cabaletta Bio (CABA) has submitted 320+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Cabaletta Bio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 8-K submitted on May 4, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CABA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners